Please login to the form below
Manish Singh resigns as CEO of ImmunoCellular Therapeutics
Replaced on interim basis by company chair and chief scientific officer Dr John Yu
Dr Manish Singh has stepped down as CEO of ImmunoCellular Therapeutics to be replaced by the company's founder Dr John Yu (pictured) on an interim basis.
US-based cancer specialist ImmunoCellular said that Dr Singh has left to "pursue other opportunities" having joined as president and CEO of the company in February 2008.
In that time, the company has focused on its lead candidate ICT-107, a cell-based vaccine in phase II development to target glioblastoma brain tumours.
The drug's progress will now be overseen by Dr Yu, who asserted his confidence in the treatment's potential, as well as ImmunoCellular's other pipeline products.
“We hope that this trial will provide clinical validation of our platform and represent a potential breakthrough treatment for this deadly and intractable cancer," he said.
“We intend to continue to make progress in advancing our earlier stage product candidates, with the recent approval of an IND to initiate a phase I trial of ICT-121 targeting CD133-positive cancer stem cells. We are developing a phase I study with ICT-140 to treat ovarian cancer.”
Dr Yu is the chief scientific officer and chair of ImmunoCellular in addition to serving on the faculty of the Department of Neurosurgery at Cedars-Sinai Medical Center.
He will continue as interim CEO while a search for a permanent replacement for Dr Singh is carried out.
Subscribe to our email news alerts
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
- Man vs microbe: the fight against antimicrobial resistance
- Dollo's law
No results were found
Latest intelligence
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
- HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL
- In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach....
